Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 7.7% – Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price was up 7.7% during trading on Friday . The company traded as high as $81.47 and last traded at $82.3290. Approximately 363,875 shares traded hands during trading, a decline of 60% from the average daily volume of 906,263 shares. The stock had previously closed at $76.45.

Analyst Ratings Changes

A number of equities analysts have recently commented on DNTH shares. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Robert W. Baird increased their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Performance

The firm has a market cap of $4.49 billion, a price-to-earnings ratio of -19.87 and a beta of 1.18. The business’s 50-day moving average is $87.10 and its 200-day moving average is $65.07.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Activity

In other news, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at $362,480. The trade was a 86.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Ryan Savitz sold 8,224 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the sale, the executive vice president owned 8,224 shares of the company’s stock, valued at approximately $738,844.16. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 149,121 shares of company stock valued at $12,635,454 in the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. Vanguard Group Inc. boosted its stake in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares during the last quarter. Patient Square Capital LP bought a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $4,919,000. UBS Group AG boosted its stake in Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after acquiring an additional 469,547 shares during the last quarter. SG Americas Securities LLC bought a new position in Dianthus Therapeutics during the 4th quarter worth approximately $765,000. Finally, Fairmount Funds Management LLC boosted its stake in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after acquiring an additional 600,000 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.